Clinical Trial Detail

NCT ID NCT02392676
Title Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Recruitment Withdrawn
Gender female
Phase Phase III
Variant Requirements No
Sponsors AstraZeneca
Indications

ovary epithelial cancer

fallopian tube cancer

peritoneal carcinoma

Therapies

Olaparib

Age Groups: adult

No variant requirements are available.